Highlights
A collection of news and information related to Lilly Eli & Co published by this site and its partners.
Displaying items 1-12 of 140
» View chicagobreakingbusiness.com items only
1
2
3
4
5
6
7
8
9
10
11-12
•
Next >
-
Denner added as nominee to Vivus board by activist investor
ReutersBy Bill Berkrot May 23 (Reuters) - First Manhattan Company (FMC) added some heavyweight muscle on Thursday to its bid to shake up the board of drugmaker Vivus Inc by naming former Carl Icahn top lieutenant Alex Denner and two others to its slate of...Tags: Carl Icahn, Science and Technology, Vivus Inc., Companies and Corporations, Manhattan (New York City)
-
ANALYSIS-Amazon gets help to lure big business to the cloud
Reuters(Repeats with no changes to text or headline) * Amazon has built up network of more than 4,000 cloud partners * Partners help satisfy more demanding enterprise customers * Crucial as Amazon targets $300 billion market By Alistair Barr SAN FRANCISCO,...Tags: Oracle Corp., Greyhound Lines Incorporated, IBM, Marketing, Adobe Systems Inc.
-
U.S. RESEARCH ROUNDUP: AIG, Express Scripts, Eli Lilly, Carlyle Group
ReutersMay 13 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S. companies, including AIG, Carlyle Group and Express Scripts, on Monday. HIGHLIGHTS * AIG : Barclays raises to overweight from equal weight -...Tags: Corning Incorporated, Pharmacyclics Incorporated, Bill Barrett Corporation, Orbotech Limited, Gilead Sciences Inc.
-
Eli Lilly's lymphoma drug fails in late-stage trial
ReutersMay 10 (Reuters) - Eli Lilly and Co said it will stop developing its experimental cancer drug after a late-stage trial failed to show a statistically significant increase in patients' disease-free survival. The drug, enzastaurin, was being tested in...Tags: Lymphoma, Health Treatments, Cancer, Chemotherapy
-
Company that lobbied for 'Obamacare' now calls key provision 'catastrophic'
Washington TimesThe head of a drug manufacturer that lobbied on behalf of "Obamacare" now has come out swinging on one key aspect of the plan -- the requirement for more tax rebates for dual Medicaid-Medicare recipients. Eli Lilly & Co. CEO John Lechleiter said the...Tags: State of the Union Address, Health Insurance, White House, Government Health Care, Medicare
-
BRIEF: Amgen announces results of colorectal cancer drug trial
Ventura County StarIn a head-to-head trial evaluating Amgen colorectal cancer treatment drug Vectibix (panitumumab) against Erbitux (cetuximab), the estimated overall survival ratio favored Vectibix, Amgen said Tuesday. Erbitux is made and distributed by Bristol-Myers...Tags: Amgen Inc., Colon Cancer, Bristol Myers Squibb Company
-
REUTERS SUMMIT-Novo's long-term targets hinge on two drugs -CEO
Reuters(For other news from Reuters Health Summit, click on http://www.reuters.com/summit/Health13) * Danish group under pressure after U.S. Tresiba setback * CEO says obesity drug could keep profit goals on track * Novo expects liraglutide for obesity to...Tags: Medical Research, Diabetes, Body Mass Index, Food and Drug Administration, Marketing
-
Lilly CEO Lechleiter to undergo surgery for dilated aorta
ReutersMay 6 (Reuters) - Drug maker Eli Lilly and Co said Chief Executive John Lechleiter will undergo a surgery on May 13 to treat a dilated aorta but is expected to recover and return to work by this summer. Chief Financial Officer Derica Rice will serve as...Tags: Symptoms, Companies and Corporations, Corporate Officers, Economy, Business and Finance, Swelling
-
February 26, 2002: Bowen lends voice to look at Reagan
BREMEN -- Dr. Otis R. Bowen, who celebrates his 84th birthday today, is already a permanent fixture in his hometown of Bremen, but later this year, he'll also become a permanent fixture in the Ronald Reagan library and museum. As a former Indiana...Tags: Notre Dame Fighting Irish, Government, Health and Medical Professionals, Executive Branch, University of Virginia
-
Eli Lilly amplía oferta en diabetes para reforzar presencia en mercado
ReutersPor Ludwig Burger y Frank Siebelt FRANCFORT (Reuters) - Eli Lilly, el cuarto fabricante mundial de medicamentos para la diabetes, buscará tener la variedad más amplia posible de fármacos antidiabéticos con el fin de ganar una mayor porción de ese...Tags: Diabetes, Byetta (drug), Januvia (drug), AstraZeneca Plc, Merck & Company Incorporated
-
Lilly broadens diabetes offer with eye on bigger slice of booming market
Reuters* Head of diabetes says eyeing broadest portfolio in industry * Aiming to win bigger slice of growing market * Lilly currently No.4 in $40 bln diabetes market * Lilly says mainly addressing GPs, not specialists By Ludwig Burger and Frank Siebelt...Tags: Byetta (drug), Denmark, Drug Trafficking, Chemical Industry, AstraZeneca Plc
-
Veeva Systems planning initial public offering - sources
ReutersBy Olivia Oran April 30 (Reuters) - Life sciences-focused software company Veeva Systems is planning an initial public offering that could come in the third quarter and has selected banks to lead the deal, according to two people familiar with the...Tags: Pharmaceuticals, Computing and Information Technology Industry, Science and Technology, Morgan Stanley Dean Witter & Company, Chemical Industry
May 23, 2013
|Story| Reuters
May 15, 2013
|Story| Reuters
May 13, 2013
|Story| Reuters
May 10, 2013
|Story| Reuters
May 8, 2013
|Story| McClatchy-Tribune
May 8, 2013
|Story| McClatchy-Tribune
May 7, 2013
|Story| Reuters
May 6, 2013
|Story| Reuters
May 5, 2013
|Story| South Bend Tribune
May 3, 2013
|Story| Reuters
May 3, 2013
|Story| Reuters
Apr 30, 2013
|Story| Reuters
Original site for Lilly Eli & Co topic gallery.
